Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 10,000 Shares of Stock

Key Points

• CEO Helen Torley sold 10,000 shares on March 4 at an average price of $70.21 for $702,100 and has sold a total of 60,000 shares across Feb. 3–Mar. 4, reducing her stake to 767,780 shares (a 1.29% ownership decrease).
• Halozyme reported an unexpected EPS miss of ($0.24) versus a $1.92 estimate, while revenue of $451.8M slightly beat expectations and rose 51.6% year‑over‑year; analysts' consensus is a Hold with an average price target of $78.56 and mixed ratings.
• Shares traded up 0.9% to $70.02, the company has a market cap of $8.26B and a P/E of 28.12, and institutional investors own about 97.8% of the stock.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 10,000 shares of the company's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $70.21, for a total value of $702,100.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company's stock, valued at $53,905,833.80. This represents a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Helen Torley also recently made the following trade(s):

• On Monday, March 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.69, for a total value of $1,393,800.00.
• On Thursday, February 5th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $78.64, for a total transaction of $786,400.00.
• On Tuesday, February 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $76.12, for a total transaction of $1,522,400.00.

Halozyme Therapeutics Stock Up 0.9%

NASDAQ:HALO traded up $0.62 on Wednesday, hitting $70.02. 1,684,507 shares of the company's stock were exchanged, compared to its average volume of 2,042,782. The firm has a 50-day moving average price of $72.71 and a 200-day moving average price of $70.76. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $82.22. The company has a debt-to-equity ratio of 43.89, a current ratio of 4.66 and a quick ratio of 3.66. The company has a market cap of $8.26 billion, a P/E ratio of 28.12, a price-to-earnings-growth ratio of 0.28 and a beta of 0.98.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.92 by ($2.16). The company had revenue of $451.77 million during the quarter, compared to analyst estimates of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. Halozyme Therapeutics's revenue was up 51.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.26 EPS. As a group, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on HALO. Wells Fargo & Company boosted their price objective on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 19th. Benchmark lifted their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a "buy" rating in a research note on Thursday, February 19th. Weiss Ratings cut Halozyme Therapeutics from a "buy (b-)" rating to a "hold (c)" rating in a research note on Tuesday, February 24th. The Goldman Sachs Group reaffirmed a "sell" rating and set a $56.00 target price on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Finally, Citizens Jmp upped their price target on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the company a "market outperform" rating in a research note on Tuesday, November 4th. Six analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $78.56.

Institutional Trading of Halozyme Therapeutics

Several large investors have recently bought and sold shares of HALO. MidFirst Bank bought a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at approximately $210,000. Pacer Advisors Inc. grew its stake in shares of Halozyme Therapeutics by 95.7% during the fourth quarter. Pacer Advisors Inc. now owns 937,293 shares of the biopharmaceutical company's stock worth $63,080,000 after buying an additional 458,419 shares during the last quarter. Corient Private Wealth LLC increased its holdings in shares of Halozyme Therapeutics by 1,552.5% during the fourth quarter. Corient Private Wealth LLC now owns 196,329 shares of the biopharmaceutical company's stock worth $13,213,000 after buying an additional 184,448 shares in the last quarter. Caitlin John LLC bought a new position in shares of Halozyme Therapeutics in the 4th quarter valued at $465,000. Finally, First Citizens Bank & Trust Co. boosted its holdings in shares of Halozyme Therapeutics by 2.8% during the 4th quarter. First Citizens Bank & Trust Co. now owns 8,913 shares of the biopharmaceutical company's stock valued at $600,000 after acquiring an additional 242 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.